A single German center experience with intermittent inotropes for patients on the high-urgent heart transplant waiting list

Clinical Research in Cardiology

Volumn 104, Issue 11, 2015, Pages 929-934

  Hubner T ^a   Nickel, T ^a   Steinbeck, G ^b   Massberg, S ^c   Schramm, R ^d   Reichart, B ^c   Hagl, C ^d   Kiwi, A ^a   Weis, Michael ^a  

^a Krankenhaus Neuwittelsbach   (Germany)

^b Zentrum für Kardiologie und Angiologie am Klinikum Starnberg   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

Heart failure; Heart transplantation; Inotropic therapy; Intensive care medicine

Indexed keywords

ADRENALIN; ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOBUTAMINE; IVABRADINE; LEVOSIMENDAN; LOOP DIURETIC AGENT; MILRINONE; NORADRENALIN; VASODILATOR AGENT; CARDIOTONIC AGENT;

ADULT; ARTICLE; BIVENTRICULAR ASSIST DEVICE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HEART GRAFT; HEART INDEX; HUMAN; INTENSIVE CARE UNIT; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PARACENTESIS; RETROSPECTIVE STUDY; TACHYPHYLAXIS; TELEMETRY; THORACOCENTESIS; CLINICAL TRIAL; DONOR; EPIDEMIOLOGY; FEMALE; GERMANY; HEART TRANSPLANTATION; HOSPITAL ADMISSION; MALE; MORTALITY; PREMEDICATION; PREOPERATIVE CARE; PREVALENCE; RISK FACTOR; SUPPLY AND DISTRIBUTION; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; CARDIOTONIC AGENTS; FEMALE; GERMANY; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; MALE; PREMEDICATION; PREOPERATIVE CARE; PREVALENCE; RISK FACTORS; SURVIVAL RATE; TISSUE DONORS; TREATMENT OUTCOME; WAITING LISTS;

EID: 84945471245     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-015-0852-1     Document Type: Article

References (28)

1. Felker GM, O’Connor CM (2001) Inotropic therapy for heart failure: an evidence-based approach. Am Heart J 142:393–401
2. Mortara A, Oliva F, Metra M, Carbonieri E, Di Lenarda A, Gorini M, Midi P, Senni M, Urso R, Lucci D, Maggioni AP, Tavazzi L (2014) Treatment with inotropes and related prognosis in acute heart failure: contemporary data from the italian network on heart failure (in-hf) outcome registry. J Heart Lung Transplant 33:1056–1065
3. Gorodeski EZ, Chu EC, Reese JR, Shishehbor MH, Hsich E, Starling RC (2009) Prognosis on chronic dobutamine or milrinone infusions for stage d heart failure. Circ Heart Fail 2:320–324
4. Liang CS, Sherman LG, Doherty JU, Wellington K, Lee VW, Hood WB Jr (1984) Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine. Circulation 69:113–119
5. Hatzizacharias A, Makris T, Krespi P, Triposkiadis F, Voyatzi P, Dalianis N, Kyriakidis M (1999) Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure. Am Heart J 138:241–246
6. Thackray S, Easthaugh J, Freemantle N, Cleland JG (2002) The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail 4:515–529
7. Bayram M, De Luca L, Massie MB, Gheorghiade M (2005) Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol 96:47G–58G
8. Levin R, Porcile R, Tanus E, Degrange M (2009) The intermittent infusion of levosimendan reduces mortality and re-admisions in patients with advanced heart failure (abstract). Circulation 120:S865
9. Bergh CH, Andersson B, Dahlstrom U, Forfang K, Kivikko M, Sarapohja T, Ullman B, Wikstrom G (2010) Intravenous levosimendan versus dobutamine in acute decompensated heart failure patients on beta-blockers. Eur J Heart Fail 12:404–410
10. Bonios MJ, Terrovitis JV, Drakos SG, Katsaros F, Pantsios C, Nanas SN, Kanakakis J, Alexopoulos G, Toumanidis S, Anastasiou-Nana M, Nanas JN (2011) Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure. Int J Cardiol 159:225–229
11. Nanas JN, Kontoyannis DA, Alexopoulos GP, Anastasiou-Nana MI, Tsagalou EP, Stamatelopoulos SF, Moulopoulos SD (2001) Long-term intermittent dobutamine infusion combined with oral amiodarone improves the survival of patients with severe congestive heart failure. Chest 119:1173–1178
12. Nanas JN, Tsagalou EP, Kanakakis J, Nanas SN, Terrovitis JV, Moon T, Anastasiou-Nana MI (2004) Long-term intermittent dobutamine infusion, combined with oral amiodarone for end-stage heart failure: a randomized double-blind study. Chest 125:1198–1204
13. Mavrogeni S, Giamouzis G, Papadopoulou E, Thomopoulou S, Dritsas A, Athanasopoulos G, Adreanides E, Vassiliadis I, Spargias K, Panagiotakos D, Cokkinos DV (2007) A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure. J Card Fail 13:556–559
14. Lilleberg J, Laine M, Palkama T, Kivikko M, Pohjanjousi P, Kupari M (2007) Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail 9:75–82
15. Malfatto G, Della Rosa F, Villani A, Rella V, Branzi G, Facchini M, Parati G (2007) Intermittent levosimendan infusions in advanced heart failure: favourable effects on left ventricular function, neurohormonal balance, and one-year survival. J Cardiovasc Pharmacol 60:450–455
16. Silvetti S, Greco T, Licia Di Prima A, Mucchetti M, Maria de Lurdes C, Pasin L, Scandroglio M, Landoni G, Zangrillo A (2014) Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials. Clin Res Cardiol 103:505–513
17. Tuomainen P, Magga J, Timonen P, Miettinen K, Kurttila M, Vanninen E, Laitinen T, Timonen K, Punnonen K, Parviainen I, Uusaro A, Vuolteenaho O, Kivikko M, Peuhkurinen K (2013) Intermittent levosimendan treatment in patients with severe congestive heart failure. Clin Res Cardiol 102:485–493
18. Zobel C, Dörpinghaus M, Reuter H, Erdmann E (2012) Mortality in a cardiac intensive care unit. Clin Res Cardiol 101:521–524
19. Adamopoulos S, Piepoli M, Qiang F, Pissimissis E, Davies M, Bernardi L, Forfar C, Sleight P, Coats A (1995) Effects of pulsed beta-stimulant therapy on beta-adrenoceptors and chronotropic responsiveness in chronic heart failure. Lancet 345:344–349
20. Leier CV, Binkley PF (1998) Parenteral inotropic support for advanced congestive heart failure. Prog Cardiovasc Dis 41:207–224
21. Unverferth DV, Magorien RD, Altschuld R, Kolibash AJ, Lewis RP, Leier CV (1983) The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy. Am Heart J 106:29–34
22. Colombo PC, Banchs JE, Celaj S, Talreja A, Lachmann J, Malla S, DuBois NB, Ashton AW, Latif F, Jorde UP, Ware JA, LeJemtel TH (2005) Endothelial cell activation in patients with decompensated heart failure. Circulation 111:58–62
23. Binkley PF, Van Fossen DB, Nunziata E, Unverferth DV, Leier CV (1990) Influence of positive inotropic therapy on pulsatile hydraulic load and ventricular-vascular coupling in congestive heart failure. J Am Coll Cardiol 15:1127–1135
24. Unverferth DV, Leier CV, Magorien RD, Croskery R, Svirbely JR, Kolibash AJ, Dick MR, Meacham JA, Baba N (1980) Improvement of human myocardial mitochondria after dobutamine: a quantitative ultrastructural study. J Pharmacol Exp Ther 215:527–532
25. Jessup M, Banner N, Brozena S, Campana C, Costard-Jackle A, Dengler T, Hunt S, Metra M, Rahmel A, Renlund D, Ross H, Warner Stevenson L (2006) Optimal pharmacologic and non-pharmacologic management of cardiac transplant candidates: approaches to be considered prior to transplant evaluation: International society for heart and lung transplantation guidelines for the care of cardiac transplant candidates–2006. J Heart Lung Transplant 25:1003–1023
26. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL (2013) 2013 accf/aha guideline for the management of heart failure: a report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation 128:e240–e327
27. Teerlink JR, Metra M, Zaca V, Sabbah HN, Cotter G, Gheorghiade M, Cas LD (2009) Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. Heart Fail Rev 14:243–253
28. De Luca L (2014) Inotropic agents in advanced heart failure: repetita iuvant? Int J Cardiol 176:6–7